Literature DB >> 20824815

Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia.

Fiona D M van Schaik1, Fiebo J W ten Kate, G Johan A Offerhaus, Marguerite E I Schipper, Frank P Vleggaar, C Janneke van der Woude, Pieter C F Stokkers, Dirk J de Jong, Daan W Hommes, Ad A van Bodegraven, Peter D Siersema, Bas Oldenburg.   

Abstract

BACKGROUND: The natural behavior of flat low-grade (LGD) and indefinite dysplasia (IND) in patients with inflammatory bowel disease (IBD) remains uncertain and seems to be dependent on the interpretation of the pathologist. We studied the progression rate of flat LGD and IND to advanced neoplasia (high-grade dysplasia [HGD] or colorectal cancer [CRC]) before and after histopathological review by a panel of gastrointestinal expert pathologists.
METHODS: A nationwide pathology database was used to identify IBD patients with dysplasia in six Dutch university medical centers between 1990 and 2006. Medical charts of patients with recorded flat LGD or IND were reviewed. Histological slides from three university medical centers were reviewed by a panel of three expert gastrointestinal pathologists.
RESULTS: We identified 113 flat LGD patients and 26 flat IND patients. Advanced neoplasia was found in 18 flat LGD patients (16%) after a median follow-up of 48 months, resulting in a 5-year progression rate of 12%. Five IND patients (19%) developed advanced neoplasia after a median follow-up of 24 months, resulting in a 5-year progression rate of 21%. Review of 1547 histological slides from 87 patients resulted in an increase of the 5-year progression rate of flat LGD to advanced neoplasia to 37%, whereas the progression rate of IND decreased to 5%.
CONCLUSIONS: A diagnosis of flat LGD that is confirmed by a panel of expert gastrointestinal pathologists is associated with a substantial risk of progression to advanced neoplasia, while confirmed IND is associated with a low risk of progression.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20824815     DOI: 10.1002/ibd.21467

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease.

Authors:  Samir A Shah; David T Rubin; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2014-09

2.  Chromoendoscopy for Surveillance in Inflammatory Bowel Disease Does Not Increase Neoplasia Detection Compared With Conventional Colonoscopy With Random Biopsies: Results From a Large Retrospective Study.

Authors:  E Mooiweer; A E van der Meulen-de Jong; C Y Ponsioen; H H Fidder; P D Siersema; E Dekker; B Oldenburg
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

Review 3.  Colon Cancer: Inflammation-Associated Cancer.

Authors:  Sherief Shawki; Jean Ashburn; Steven A Signs; Emina Huang
Journal:  Surg Oncol Clin N Am       Date:  2017-12-15       Impact factor: 3.495

4.  Clinical significance of indefinite for dysplasia on pouch biopsy in patients with underlying inflammatory bowel disease.

Authors:  Zhao-Xiu Liu; Xiu-Li Liu; Deepa T Patil; Lei Lian; Ravi P Kiran; Feza H Remzi; Run-Zhou Ni; Bo Shen
Journal:  J Gastrointest Surg       Date:  2011-11-29       Impact factor: 3.452

Review 5.  Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis.

Authors:  Sara Lauricella; Silvia Fabris; Patricia Sylla
Journal:  Surg Endosc       Date:  2022-08-03       Impact factor: 3.453

6.  Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview.

Authors:  Chang-Ho Ryan Choi; Matthew D Rutter; Alan Askari; Gui Han Lee; Janindra Warusavitarne; Morgan Moorghen; Siwan Thomas-Gibson; Brian P Saunders; Trevor A Graham; Ailsa L Hart
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

7.  Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia.

Authors:  Bela Horvath; Ganglei Liu; Xianrui Wu; Keith K Lai; Bo Shen; Xiuli Liu
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-06-10

8.  No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases.

Authors:  Remi Mahmoud; Shailja C Shah; Joren R Ten Hove; Joana Torres; Erik Mooiweer; Daniel Castaneda; Jason Glass; Jordan Elman; Akash Kumar; Jordan Axelrad; Thomas Ullman; Jean-Frederic Colombel; Bas Oldenburg; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2018-12-07       Impact factor: 22.682

9.  Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer.

Authors:  Chang-ho Ryan Choi; Ana Ignjatovic-Wilson; Alan Askari; Gui Han Lee; Janindra Warusavitarne; Morgan Moorghen; Siwan Thomas-Gibson; Brian P Saunders; Matthew D Rutter; Trevor A Graham; Ailsa L Hart
Journal:  Am J Gastroenterol       Date:  2015-09-29       Impact factor: 10.864

Review 10.  Imaging of Mucosal Inflammation: Current Technological Developments, Clinical Implications, and Future Perspectives.

Authors:  Maximilian J Waldner; Timo Rath; Sebastian Schürmann; Christian Bojarski; Raja Atreya
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.